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among them central regulators of choles-
terol metabolism. Accordingly, a more
comprehensive appraisal of DHR96 func-
tion in lipometabolism has to await contin-
uative, functional studies on its other
target genes. As it is the baton which
grants the conductors control over the
orchestra, it is the ligand which empowers
nuclear receptors. As yet DHR96 is an
orphan nuclear receptor but belongs to
a family in which some members made
their career as prominent drug targets.
Accordingly, the identification of the
endogenous DHR96 ligand(s) is an out-
standing future challenge in view of the
potential functional conservation among
the xenobiotic receptors of flies and man
with respect to the presented novel
mode of fat storage control.
Showing that Orlistat slims Drosophila
is not only good news for flies concerned
about their ‘‘wasp waists.’’ This finding
also provides proof of concept for small
compound in vivo screens to identify
modulators of dietary fat digestion using
the fly model. Collectively, this study
underscores the value of Drosophila as
a rising model system for energy metabo-
lism research (Baker and Thummel, 2007;
Schlegel and Stainier, 2007) with rele-
vance for the understanding of physio-
logical and pathophysiological processes
in fat storage regulation of mammals
and man.
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Cells regulate iron homeostasis by posttranscriptional regulation of proteins responsible for iron uptake and
storage. This requires RNA-binding activity of iron-regulatory proteins, IRP1 and IRP2. Two studies recently
published in Science by Vashisht et al. (2009) and Salahudeen et al. (2009) reveal how cells adjust IRP2
activity.Iron-containing enzymes are essential for
the survival of both uni- and multicellular
organisms, as they function in energy-
producing redox reactions, oxygen trans-
port, DNA synthesis, and cellular detoxifi-
cation. Iron associates with proteins most
commonly by its insertion into a porphyrin
ring as heme or its assembly with sulfur in
Fe-S clusters. In some proteins, di- or
trivalent iron is bound directly to specific
pockets in the secondary structure. Prior
to its incorporation, iron needs to be
bioavailable as ‘‘free’’ iron. This free iron
is potentially harmful because of its ability
to generate reactive oxygen species
through Fenton chemistry. Thus, cells
must carefully regulate iron homeostasis
to ensure sufficient iron supply while
limiting iron toxicity.
In mammals, two distinct regulatory
circuits control body and cellular iron
homeostasis. Body iron is sensed by theliver, which in response to high iron
synthesizes and secretes hepcidin. This
peptide hormone negatively regulates
iron export from intestinal cells to limit
iron absorption from the diet. Cellular
iron homeostasis is achieved by the cyto-
plasmic RNA-binding proteins IRP1 and
IRP2, which regulate posttranscriptionally
the fate of mRNAs encoding proteins
crucial for iron metabolism, such as trans-
ferrin receptor 1 (TfR1) and ferritin H and L
(Figure 1). At low cellular iron concentra-
tions, IRPs are active and bind to con-
served RNA hairpin structures, known as
iron-responsive elements (IREs). Binding
to five IREs in the 30 untranslated region
of TfR1 mRNA inhibits mRNA degrada-
tion, thereby increasing TfR1 expression
and iron uptake. Binding to one IRE in
the 50 untranslated region of ferritin
mRNA inhibits ferritin translation, thereby
reducing cellular iron storage. IncreasedCell Metabolism 10iron uptake and reduced iron storage
cumulatively augment the free iron pool.
High iron levels, in turn, inactivate IRP1
and IRP2 RNA-binding activity. IRP1
inserts a 4Fe-4S cluster, which converts
it into a cytosolic aconitase, while IRP2
is targeted for proteasomal degradation.
Initial studies concluded that a unique 73
amino acid region of IRP2, which is
absent in IRP1, was modified by iron-
dependent oxidation and then recognized
by heme-oxidized IRP2 ubiquitin ligase 1
(HOIL-1) (Yamanaka et al., 2003). These
conclusions were, however, contradicted
by studies showing that deletion of the
73 amino acid region or RNA interference
against HOIL-1 did not abrogate iron-
dependent IRP2 degradation (Hanson
et al., 2003; Wang et al., 2004; Zumbren-
nen et al., 2008). In addition, a constitutive
apo-IRP1 mutant was sensitive to iron-
dependent proteasomal degradation,, December 2, 2009 ª2009 Elsevier Inc. 439
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Figure 1. Mechanisms that Control Cellular Iron Homeostasis
The scheme depicts the two iron regulatory proteins, IRP1 and IRP2, which are active RNA-binding proteins at low-free-iron conditions. They control posttran-
scriptionally the fate of mRNAs encoding the most essential proteins in iron metabolism, TfR1 and ferritin (Fer), which function in cellular iron import and storage,
respectively, thus adjusting the free iron pool. Free iron contributes to the assembly of the 4Fe-4S cluster that inactivates IRP1 (light blue), converting it to a cyto-
plasmic aconitase (dark blue) and to the di-iron-oxygen center in the hemerythrin domain of FBXL5, which then binds IRP2 (fuchsia pink) and induces its degra-
dation by the proteasomal pathway. Thus, free iron acts on its own level through these elaborate feedback loops. Its steady state will equilibrate at the concen-
tration required for the iron center synthesis.suggesting a conserved mechanism of
degradation for IRP2 and apo-IRP1
(Clarke et al., 2006).
Now, two laboratories have indepen-
dently identified an E3 ubiquitin ligase
complex that is required for IRP2 degra-
dation (Vashisht et al., 2009; Salahudeen
et al., 2009). Salahudeen et al. used an
siRNA screen to identify proteins required
for the iron-dependent degradation of
IRP2. They identified FBXL5, SKP1,
cullin1 (CUL1), and RBX1, which form
the newly discovered E3 ligase complex,
as critical proteins in IRP2 iron degrada-
tion. Vashisht et al. generated an FBXL5
mutant lacking the F-box domain (FBXL5-
DF-box), which is unable to interact with
SKP1 and CUL1 and therefore functions
as a substrate-trapping reagent. Mass
spectrometry analysis of FBXL5-DF-box-
interacting proteins showed that FBXL5
interacted with both IRP2 and IRP1.
Both laboratories showed that the inter-
action between FBXL5 and IRP2 or IRP1
is iron dependent and that in vitro or
in vivo IRP2 ubiquitination is increased in
the presence of FBXL5. Furthermore,
RNA interference against FBXL5 elimi-
nated the iron-dependent degradation of
both IRP2 and apo-IRP1, indicating that
SCFFBXL5 functions as the E3 ligase for
both proteins.440 Cell Metabolism 10, December 2, 2009 ªThemechanism by which iron regulates
the interaction between FBXL5 and IRP2
was revealed by studying the stability of
FBXL5 under high- and low-iron condi-
tions. Both groups showed that FBXL5
is degraded by the proteasome when
cellular free iron was low, which presum-
ably requires yet another uncharacterized
ubiquitin ligase. FBXL5 was also destabi-
lized under low oxygen concentration.
The iron- and oxygen-dependent stability
of FBXL5 was located at its N-terminal
199 amino acids. This region is predicted
to fold into a hemerythrin-like domain
and was shown to bind iron. Hemerythrin
domains utilize histidine and carboxylate-
containing residues to coordinate a di-iron
core that can reversibly bind oxygen
(Stenkamp, 1994). Mutation of predicted
iron-binding residues within the hemery-
thrin domain of FBXL5 showed that the
domain folded appropriately only in the
presence of iron and oxygen (Salahudeen
et al., 2009). Deletion of the hemerythrin-
like domain eliminated the iron-depen-
dent regulation of FBXL5. Hemerythrin
domains have not previously been
observed in mammalian proteins, but
are known to play an important role in
oxygen sensing in bacteria (Stenkamp,
1994). Future studies will have to charac-
terize this unique mammalian hemerythrin2009 Elsevier Inc.domain. Since IRP1 also interacts with
FBXL5 (Vashisht et al., 2009), one
wonders why IRP1 escapes protein
degradation. Maybe a swift 4Fe-4S
cluster insertion alters its structure to the
extent that it is no longer recognized by
FBXL5.
We know now that two parallel mecha-
nisms control iron homeostasis, both
mediated by the insertion of iron into iron
centers (Figure 1). Why would cells need
two IRPs? IRP1 and IRP2 seem rather
redundant and show similar affinity for
known target mRNAs. However, they
also have unique in vitro binding specific-
ities (Henderson et al., 1996) that might be
reflected in unique target mRNAs in vivo.
For IRP2/ mice, anemia and mild loco-
motor dysfunction were observed, but
the phenotype is partially compensated
by IRP1, while IRP1/ mice showed
only mild changes that are well com-
pensated by IPR2 (Meyron-Holtz et al.,
2004a). Yet both proteins are essential,
as double deletions are embryonic-lethal
and phenotypic changes are severely in-
creased in IRP2/IRP1+/mice. The new
results incite us now to ask whether the
IRP1-inactivating 4Fe-4S cluster and the
di-iron-oxygen center of FBXL5 serve
the same purpose. Since Fe-S clusters
are synthesized in mitochondria, it seems
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Previewspossible that IRP1 inactivation may
depend on themitochondrial iron concen-
tration, whereas IRP2 would rather sense
cytoplasmic iron. In addition, the two iron
centers show different properties with
respect to oxygen. Assembly of 4Fe-4S
clusters is favored by low oxygen concen-
trations, as they occur in tissues (Meyron-
Holtz et al., 2004b). In contrast, stability
of the hemerythrin domain of FBXL5 and
hence IRP2 degradation is enhanced at
high oxygen concentrations (Salahudeen
et al., 2009). Therefore, having two IRPs
with different modes of regulation pro-
vides cells with the opportunity to control
iron homeostasis over a wide range of
oxygen concentrations.REFERENCES
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